This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 2 studies, archived under the term: "product surveillance postmarketing"

Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer’s disease: a prospective post-marketing surveillance study

Background and Objectives: Rivastigmine is approved for the symptomatic treatment of mild to moderate dementia in patients with Alzheimer’s disease. The drug was launched in Taiwan in 2000. The primary objective of this post-marketing surveillance (PMS) study was to describe the safety/tolerability of treatment with rivastigmine capsules in patients with Alzheimer’s disease. The secondary objectives […]

Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database

Background: Since donepezil and memantine are currently used for treating Alzheimer’s disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use.; Methods: All spontaneous reports of suspected serious adverse drug reactions with donepezil alone and with memantine alone recorded in the French Pharmacovigilance Database during 6 […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: